Abcellera Biologics Inc (ABCL)vsEli Lilly and Company (LLY)
ABCL
Abcellera Biologics Inc
$5.24
+8.71%
HEALTHCARE · Cap: $1.54B
LLY
Eli Lilly and Company
$948.45
-2.72%
HEALTHCARE · Cap: $869.41B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 96068% more annual revenue ($72.25B vs $75.13M). LLY leads profitability with a 35.0% profit margin vs -194.9%. LLY earns a higher WallStSmart Score of 78/100 (B+).
ABCL
Hold41
out of 100
Grade: D
LLY
Strong Buy78
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+64.8%
Fair Value
$8.88
Current Price
$5.24
$3.64 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 788.0% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Earnings expanding 45.9% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 108 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
Smaller company, higher risk/reward
ROE of -14.5% — below average capital efficiency
Negative free cash flow — burning cash
Currently unprofitable
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 27.2x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ABCL
The strongest argument for ABCL centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 788.0% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : ABCL
The primary concerns for ABCL are Market Cap, Return on Equity, Free Cash Flow.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABCL profiles as a hypergrowth stock while LLY is a growth play — different risk/reward profiles.
ABCL carries more volatility with a beta of 1.03 — expect wider price swings.
ABCL is growing revenue faster at 788.0% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 41/100), backed by strong 35.0% margins and 55.5% revenue growth. ABCL offers better value entry with a 64.8% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abcellera Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?